Skip to main content

Table 1 Characteristics of hormone receptor-positive patients, eligible and non-eligible for RS assessment

From: The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)

Characteristics, n (%) PACS-01 (n = 1610) Eligible (n = 530) Non-eligible (n = 1080) p
FEC-D 820 (50.9) 268 (50.6) 552 (51.1) 0.84
Age ≥ 50 years 809 (50.2) 250 (47.2) 559 (51.8) 0.08
Mastectomy 708 (44.0) 215 (40.6) 493 (45.6) 0.053
≥ 4 positive nodes 595 (37.0) 210 (39.6) 385 (35.6) 0.12
Tumor size > 20 mm 701 (47.7) 244 (49.3) 457 (46.9) 0.28
 Missing 141 35 106  
Ductal carcinoma 1204 (74.8) 381 (71.9) 823 (76.2) 0.06
SBR grade     0.31
 Grade 1 216 (14.4) 76 (15.3) 140 (14.0)  
 Grade 2 788 (52.5) 251 (50.4) 537 (53.6)  
 Grade 3 496 (33.1) 171 (34.3) 325 (32.4)  
 Missing 110 32 78  
Ki-67 expression ≥14% [19] 270 (36.7) 198 (40.5) 72 (29.1) 0.003
 Missing 874 41 833  
HER2-positive 81 (9.7) 46 (8.8) 35 (11.3) 0.23
 Missing 776 5 771  
Hormone receptor by IHC
 ER+ 1493 (92.7) 506 (95.5) 987 (91.4) 0.003
 PgR+ 1186 (73.7) 355 (67.0) 831 (76.9) <  0.001
  ER+/PgR+ 1069 (66.4) 331 (62.5) 738 (68.3) <  0.001
  ER+/PgR- 424 (26.3) 175 (33.0) 249 (23.1)  
  ER-/PgR+ 117 (7.3) 24 (4.5) 93 (8.6)  
  1. DFS disease-free survival, FEC-D 3 cycles of FEC (6 cycles of 5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2) followed by 3 cycles of docetaxel 100 mg/m2, FEC100 6 cycles of 5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2, SBR Scarff–Bloom Richardson, IHC immunohistochemistry, ER estrogen receptor, PgR progesterone receptor